French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and ...

When a new drug hits the market, it creates ripple effects that can improve the health and quality of life of patients. Some ...

Scientists have developed a gel-based version of semaglutide that could reduce how often people need to take it.

Researchers in France have developed a once-a-month hydrogel-based delivery system for semaglutide, significantly simplifying ...

An injectable hydrogel provided a sustained release of semaglutide for 1 month in rats, according to preclinical testing of an experimental longer-acting formulation.

French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and ...

GlobalData’s report assesses the drugs in the Glucagon Like Peptide 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. GLP-1 medications ...

The company secured $67m in the Series B financing round jointly led by Ascenta Capital and Woodline Partners.

GLP-1 agonists are a class of medications that mimic the effects of a hormone called glucagon-like peptide-1. These drugs slow gastric emptying and increase feelings of fullness. GLP-1 agonists also ...

New STEP-HFpEF findings presented at this year’s European Society of Cardiology Congress add to the many accolades this ...